Paradigm Strikes AVet Licensing Deal for Novel Oral Veterinary Osteoarthritis Drug

Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.

Paradigm Biopharmaceuticals has signed a binding term sheet with AVet Health to co-develop and license an oral combination of pentosan polysulfate sodium and a COX-2 inhibitor for osteoarthritis in companion animals in Australia and New Zealand. AVet will hold exclusive rights in those markets and a first right of refusal in most other territories, while Paradigm retains U.S. veterinary rights and potential development milestones of up to A$1 million.

Once a definitive licensing agreement is executed, Paradigm will control manufacturing and earn tiered royalties of up to 20 percent on net sales over a 15-year term following Australian registration. The partnership enables Paradigm to advance this first-in-class, dual-action veterinary OA therapy and generate early data in a capital-efficient way, supporting both veterinary commercialization and its broader osteoarthritis strategy alongside the pivotal Phase 3 Zilosul trial.

The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on therapies for osteoarthritis and other conditions with unmet medical needs. Its portfolio includes injectable iPPS candidate Zilosul for human osteoarthritis and a growing range of oral, non-opioid formulations targeting both human and veterinary markets, with a particular focus on earlier-stage disease management and long-term pain control.

YTD Price Performance: -14.71%

Average Trading Volume: 908,248

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$125.8M

For detailed information about PAR stock, go to TipRanks’ Stock Analysis page.